These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21798557)

  • 1. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
    Fuld K; Chi C; Neely EK
    J Pediatr; 2011 Dec; 159(6):982-7.e1. PubMed ID: 21798557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty.
    Badaru A; Wilson DM; Bachrach LK; Fechner P; Gandrud LM; Durham E; Wintergerst K; Chi C; Klein KO; Neely EK
    J Clin Endocrinol Metab; 2006 May; 91(5):1862-7. PubMed ID: 16449344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.
    Mericq V; Lammoglia JJ; Unanue N; Villaroel C; Hernández MI; Avila A; Iñiguez G; Klein KO
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):686-90. PubMed ID: 19302581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group.
    Tanaka T; Hibi I; Kato K; Saito S; Shimizu N; Suwa S; Nakajima H
    Endocrinol Jpn; 1991 Aug; 38(4):369-76. PubMed ID: 1839379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
    Cook JS; Doty KL; Conn PM; Hansen JR
    J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
    Carel JC; Lahlou N; Jaramillo O; Montauban V; Teinturier C; Colle M; Lucas C; Chaussain JL
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4111-6. PubMed ID: 12213857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy.
    Bhatia S; Neely EK; Wilson DM
    Pediatrics; 2002 Feb; 109(2):E30. PubMed ID: 11826240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty.
    Mostafa NM; Hosmane B; Larsen LM; Chwalisz K; Chiu YL; Pradhan RS
    Clin Drug Investig; 2014 Jul; 34(7):441-8. PubMed ID: 24756362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot leuprolide acetate for treatment of precocious puberty.
    Parker KL; Lee PA
    J Clin Endocrinol Metab; 1989 Sep; 69(3):689-91. PubMed ID: 2503536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Random Luteinizing Hormone is an Unreliable Indicator for Pubertal Suppression in Girls Treated with Monthly Leuprolide for Idiopathic Central Precocious Puberty.
    Wiromrat P; Panamonta O
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):227-233. PubMed ID: 30592192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.